LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) – Stock analysts at Barrington Research upped their FY2024 earnings per ...
Discover why LeMaitre's expansion in the peripheral vascular disease market and strong dividend growth make it an appealing ...
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $95.25, a high ...
Lemaitre Vascular ( (LMAT) ) has released its Q3 earnings. Here is a breakdown of the information Lemaitre Vascular presented to its investors.
5d
Lemaitre Vascular (LMAT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel ...
LeMaitre Vascular has a 52-week low of $45.96 and a 52-week high of $101.67. LeMaitre Vascular ( NASDAQ:LMAT – Get Free Report ) last issued its earnings results on Thursday, October 31st.
Technical analysis for Lemaitre Vascular Inc. LMAT including support levels resistance levels and stop losses for LMAT ...
Third Quarter 2024 Results Key Financial Results Revenue: US$54.8m (up 16% from ...
BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:LMAT) announced today that management will be participating in ...
Welcome to the LeMaitre Vascular Q3 2024 Financial Results Conference Call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. J.J. Pellegrino ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback